EGFR and non-small cell lung carcinoma: It maintains pathway functionality by employing alternative effectors, activating alternate signaling networks, or disrupting feedback signals (Fig. 5).189 In EGFR-mutant NSCLC, upregulation of AXL serves as a bypass mechanism, contributing to acquired resistance to first-generation EGFR TKIs.